MannKind CEO Is Optimistic About Near-Term Approval Of Afrezza
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MannKind CEO Alfred Mann played down a regulatory delay of the company's rapid-acting inhaled recombinant insulin product Afrezza and, in response to questions, refused to acknowledge that finding a partner could be tough, during a presentation and subsequent breakout session at the J.P. Morgan Healthcare Conference on Jan. 12
You may also be interested in...
Pfizer's Message To Wall Street: We're Doing Things Differently Now
Exubera's failure was a defining moment for CEO Jeff Kindler, who says the episode motivated him to transform the way Pfizer makes decisions.
An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011